12:00 AM
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Reolysin: Phase III ongoing

Oncolytics said an independent DMC recommended continuation of the double-blind, placebo-controlled, international Phase III REO 018 trial evaluating IV Reolysin in combination with carboplatin and paclitaxel vs. chemotherapy alone based on a review of safety data from 80 patients...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >